You are here

News

Monday, June 16, 2014

The CFAR NAb Core provides standardized assessments of the magnitude, breadth, kinetics and duration of vaccine-elicited neutralizing antibody responses in preclinical and clinical trials of candidate HIV and SIV vaccines using validated assays and standardized reference strains in a GCLP-complia

Sunday, June 15, 2014

Most grant applications are evaluated by a peer-review panel that includes a discussion of strengths and weaknesses as perceived by the reviewers.   The discussions that take place in a grant review session may greatly influence the score a grant application receives.   A better understanding of

Tuesday, June 10, 2014

Grant applications may be enhanced by pre-review prior to submission of the proposal to the funding agency.   The Developmental Core is available to provide grant proposal pre-review for HIV/AIDS research proposals.   Please contact the Developmental Core and

Monday, June 9, 2014

The BCB has executed an initiative to implement online consulting for computational or statistical issues/topics (e.g., power calculation for sample size, selection of matching controls, and reproducible research) that are commonly encountered in AIDS clinical research.

Wednesday, May 28, 2014

Please contact the CFAR Developmental Core with any requests for faculty development resources or services not currently provided.    Complaints and comments are welcome to provide continuous improvement of the services offered by the Developmental Core.

Tuesday, May 6, 2014

DURHAM, N.C. – Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.
 

Wednesday, April 16, 2014

Weekly walk-in clinics will be held on Mondays from 12:00 - 12:55 at the SORF conference room starting from March 10, 2014. Core E faculty will be present to provide ad-hoc consults to any CFAR investigator, including:

Thursday, March 27, 2014

The production of certain antibodies could explain the partial success of an HIV-vaccine trial and the failure of another.

Wednesday, March 19, 2014

What immune response should a vaccine elicit to prevent HIV infection?

Pages